Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. Community Guidelines: https://bit.ly/3C1v1wz 

Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

The ALS Association

ALS Finding a Cure

Lysosomal Therapeutics

Morningside Group

ALS Investment Fund

Morningside Venture Investments

DRADS Capital

Woodline Partners

Marshall Wace

Perceptive Advisors

Polaris Founders Capital

Tybourne Capital Management

Verition Fund Management

683 CAPITAL

aMoon Fund

Belinda Termeer

Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com. 

With a new year upon us, we’re eager to continue our fight of addressing the unmet needs of those with #ALS and other #neurodegenerative diseases. There is no time to waste.

Today we announced the first participant dosed in the largest #progressivesupranuclearpalsy study to date. This Phase 3 #clinicaltrial for the treatment of #PSP will enroll approximately 600 participants across ~100 sites in the U.S., Canada, the EU, the UK, and Japan.
Read more: https://lnkd.in/enCfTTKU 

As 2023 draws to a close, we’re also reflecting on 10 years of Amylyx. We’d like to show our gratitude to the incredible determination of the #ALS and #neurodegenerative community, as well as our extraordinary global colleagues who show up every day with the shared mission of one day ending the suffering caused by neurodegenerative diseases.

At Amylyx, we’ve created a culture that uses unconventional thinking for unsolved problems. We learn from one another through our collective experience, and we share a connection in our common purpose. 
Does this sound like you? 
See our current openings: https://lnkd.in/eDq_3vK4 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue		650K -	285K 56.15%	22.23M 7,700%	380.79M 1,612.94%
cost of revenue				2.99M -	25.44M 750.02%
gross profit		650K -	285K 56.15%	19.24M 6,649.82%	355.35M 1,747.20%
selling and marketing expenses
general and administrative expenses	3.08M -	15.06M 388.83%	38.93M 158.50%
selling general and administrative expenses	3.08M -	15.06M 388.83%	38.93M 158.50%	127.13M 226.53%	188.36M 48.16%
research and development expenses	11.90M -	24.59M 106.69%	44.04M 79.07%	93.45M 112.19%	128.19M 37.17%
other expenses	-1.43M -	-650K 54.42%	-285K 56.15%	3.74M 1,412.28%	-660K 117.65%
cost and expenses	13.55M -	39.01M 187.77%	82.69M 111.99%	223.57M 170.38%	341.98M 52.96%
operating expenses	13.55M -	39.01M 187.77%	82.69M 111.99%	220.58M 166.76%	316.54M 43.51%
interest expense	1.28M -	2.29M 79.31%		4.29M -
ebitda	-13.38M -	-38.72M 189.42%	-82.69M 113.55%	-201.34M 143.49%	39.89M 119.81%
operating income	-13.55M -	-39.01M 187.77%	-82.69M 111.99%	-201.34M 143.49%	38.80M 119.27%
depreciation and amortization	175K -	284K 62.29%	52K 81.69%	487K 836.54%	1.09M 123.41%
total other income expenses net	-162K -	-3.27M 1,921.60%	-5.24M 60.09%	3.74M 171.33%	-660K 117.65%
income before tax	-13.72M -	-42.28M 208.25%	-87.93M 107.97%	-197.60M 124.72%	54.30M 127.48%
income tax expense	1.10M -	2.56M 132.45%	-52K 102.03%	774K 1,588.46%	5.03M 549.35%
net income	-14.82M -	-44.84M 202.63%	-87.88M 96.00%	-198.38M 125.74%	49.27M 124.84%
weighted average shs out	45.55M -	45.95M 0.88%	55.22M 20.16%	58.50M 5.94%	67.23M 14.94%
weighted average shs out dil	45.55M -	45.95M 0.88%	55.22M 20.16%	58.50M 5.94%	69.99M 19.65%
eps	-0.33 -	-0.98 196.97%	-1.59 62.24%	-3.39 113.21%	0.73 121.53%
epsdiluted	-0.33 -	-0.98 196.97%	-1.59 62.24%	-3.39 113.21%	0.70 120.65%

COM:AMYLYX

Amylyx Pharmaceuticals, Inc.

Last Close

5.19

22/11 21:00

Market Cap

140.77M

Beta: -

Volume Today

831.95K

Avg: -

Preview